Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 1, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons regarding the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
On July 29, 2005, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 22,992 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The GSK Trust is a discretionary trust benefiting current and former employees. Three directors—Dr. J-P Garnier, Dr. T Yamada, and Mr. J S Heslop—hold interests in the shares held by the GSK Trust in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- 22,992 Ordinary Shares were transferred from the GSK Trust to employee plan participants on July 29, 2005.
- Three directors have an indirect interest in the GSK Trust shares alongside other employees.
- This filing does not contain financial performance data for the period.